Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > keep the enthusiasm in check

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Mar 26, 2023 1:34pm

187 Views

Post# 35361320

RE:RE:RE:RE:RE:keep the enthusiasm in check

Yes the quickest path to full approval but not guaranteed no matter what you say.
So you are suggesting to all of the people that follow you that if a 2 billion offer was put forward to shareholders , a guaranteed sale and money in their pocket that you would reccommend that we all turn the offer down. Nothing personal and as much as I do appreciate some of your posts, you are not nearly as savey as some may think you are.
Also Potential use of bio-markers as stated in the current onc presentation.

<< Previous

Bullboard Posts

Next >>

B2Gold stock buckles under news of labour strike in Mali